Who are GSK Biologicals' AS01B adjuvant's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Low Dose Naloxone, ERITORAN, MgSO4 plus Ropivacaine, H5N1 vaccine (Arepanrix), ropivacaine plus clonidine, Bleomycin + Fibrovein.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/gsk-biologicals-as01b-adjuvant.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

GSK Biologicals' AS01B adjuvant — Competitive Intelligence Brief

GSK Biologicals' AS01B adjuvant (GSK Biologicals' AS01B adjuvant) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Adjuvant. Area: Vaccines.

phase 2 Adjuvant Toll-like receptor 4 Vaccines Biologic Live · refreshed every 30 min

Target snapshot

GSK Biologicals' AS01B adjuvant (GSK Biologicals' AS01B adjuvant) — GlaxoSmithKline. Stimulates Toll-like receptor 4 and MyD88-dependent signaling pathway

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
GSK Biologicals' AS01B adjuvant TARGET	GSK Biologicals' AS01B adjuvant	GlaxoSmithKline	phase 2	Adjuvant	Toll-like receptor 4
Low Dose Naloxone	Low Dose Naloxone	University of Texas Southwestern Medical Center	phase 3	Opioid receptor antagonist (low-dose formulation)	Toll-like receptor 4 (TLR4); opioid receptors (mu, delta, kappa) at sub-blocking doses
ERITORAN	ERITORAN		phase 3		Toll-like receptor 4
MgSO4 plus Ropivacaine	MgSO4 plus Ropivacaine	Hospital Universiti Sains Malaysia	marketed	Local anesthetic adjuvant combination	Voltage-gated sodium channels (ropivacaine); NMDA receptors and calcium channels (magnesium sulfate)
H5N1 vaccine (Arepanrix)	H5N1 vaccine (Arepanrix)	Canadian Immunization Research Network	marketed	inactivated split-virion influenza vaccine with adjuvant
ropivacaine plus clonidine	ropivacaine plus clonidine	University Hospital, Lille	marketed	Local anesthetic with adjuvant alpha-2 agonist	Voltage-gated sodium channels (ropivacaine); alpha-2 adrenergic receptors (clonidine)
Bleomycin + Fibrovein	Bleomycin + Fibrovein	Oslo University Hospital	marketed	Chemotherapy agent with hemostatic adjuvant	DNA (bleomycin); fibrin polymerization (fibrovein)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Adjuvant class)

GlaxoSmithKline · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). GSK Biologicals' AS01B adjuvant — Competitive Intelligence Brief. https://druglandscape.com/ci/gsk-biologicals-as01b-adjuvant. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab